XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.81

+1.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (15889)	7/17/2002 12:35:25 AM
From: Bluegreen	Read Replies (2) of 17367

Cacaito, here it is from Genentech website>>>>>>>>>>>>>>Immunological Disease & Other Unmet Needs Xanelim™ (Efalizumab): Genentech met with the FDA during the second quarter of 2002 to discuss the Xanelim filing strategy. Contingent upon a positive outcome in the ongoing Phase III efficacy trial using Genentech material, the company will plan on filing a Biologic License Application to the FDA by the fourth quarter of this year.<<<<<<< Once again how would the FDA allow a company to file a BLA WITHOUT a positive outcome???? Obviously you are confusing people which I am sure is unintentional. It sure is a shame when you reduce this board to the point where I have to go to the source to clear up your bungling jargon.LOL Do you also see where the statement says BY the fourth quarter???

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next